Pharmacokinetics, safety, and tolerability of etrasimod (APD334) in subjects with mild, moderate, or severe hepatic impairment: a single-dose, open-label, parallel-group study

被引：2
|
作者：
Lee, C. [1 ]
Tang, Y. [1 ]
Schroeder, C. [1 ]
Zhang, J. [1 ]
Nguyen-Cleary, T. [1 ]
Mullin, S. [1 ]
Ma, M. [1 ]
Lyon, N. [1 ]
Grundy, J. [1 ]
机构：
[1] Arena Pharmaceut Inc, San Diego, CA USA
来源：
JOURNAL OF CROHNS & COLITIS | 2021年 / 15卷
关键词：
D O I：
10.1093/ecco-jcc/jjab076.415
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P291
引用
收藏
页码：S321 / S322
页数：4
相关论文
共 50 条
  • [31] Pharmacokinetics and Safety of Single-Dose Esaxerenone in Japanese Subjects with Mild to Moderate Hepatic Impairment
    Kurata, Akifumi
    Yoshida, Takafumi
    Inoue, Megumi
    Ishizuka, Tomoko
    Nakatsu, Takafumi
    Shimizu, Takako
    Kato, Manabu
    Nishikawa, Yasuhiro
    Ishizuka, Hitoshi
    ADVANCES IN THERAPY, 2020, 37 (01) : 253 - 264
  • [32] Pharmacokinetics and Pharmacodynamics of Cinacalcet in Hepatic ImpairmentPhase I, Open-Label, Parallel-Group, Single-Dose, Single-Centre Study
    Desmond Padhi
    Robert Z. Harris
    Margaret Salfi
    Robert J. Noveck
    John T. Sullivan
    Clinical Drug Investigation, 2008, 28 : 635 - 643
  • [33] An Open-Label, Single-Dose, Parallel-Group, Dose-Increasing Study Comparing the Pharmacokinetics and Tolerability of Pilsicainide Hydrochloride in Healthy Korean and Japanese Male Subjects
    Kim, Bo-Hyung
    Kim, Jung-Ryul
    Lim, Kyoung Soo
    Kim, Jae Woo
    Kim, Kyu-pyo
    Hong, Jang-Hee
    Jang, In-Jin
    Shin, Sang-Goo
    Yu, Kyung-Sang
    Tanaka, Takanori
    CLINICAL THERAPEUTICS, 2009, 31 (03) : 609 - 618
  • [34] Single-Dose Pharmacokinetics, Safety, and Tolerability of Avadomide (CC-122) in Subjects With Mild, Moderate, or Severe Renal Impairment
    Li, Yan
    MacGorman, Kimberly
    Liu, Liangang
    Chen, Jian
    Hoffmann, Matthew
    Palmisano, Maria
    Zhou, Simon
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2020, 9 (07): : 785 - 796
  • [35] Pharmacokinetics and Safety of Multiple-Dose Alpelisib in Participants with Moderate or Severe Hepatic Impairment: A Phase 1, Open-Label, Parallel Group Study
    Marbury, Thomas
    El-Hashimy, Mona
    Blumenstein, Lars
    Letellier, Franck
    Sengupta, Tirtha
    Lorenzo, Sebastien
    Preston, Richard Alfred
    JOURNAL OF CANCER, 2023, 14 (09): : 1571 - 1578
  • [36] The Pharmacokinetics, Safety, and Tolerability of Rimegepant 75 mg are Similar in Elderly and Nonelderly Adults: a Phase 1, Open-Label, Parallel-Group, Single-Dose Study
    Croop, R.
    Stringfellow, J.
    Ivans, A.
    Coric, V
    HEADACHE, 2019, 59 : 177 - 178
  • [37] The Pharmacokinetics, Safety, and Tolerability of Rimegepant 75 mg Are Similar in Elderly and Nonelderly Adults: A Phase 1, Open-Label, Parallel-Group, Single-Dose Study
    Bhardwaj, Rajinder
    Morris, Beth
    Bertz, Richard
    Croop, Robert
    Liu, Jing
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2024, 13 (01): : 37 - 44
  • [38] An open-label comparative study of the pharmacokinetics and tolerability of zibotentan (ZD4054) in subjects with mild, moderate, or severe hepatic impairment, or normal hepatic function
    Kemp, John
    Tomkinson, Helen
    Taboada, Maria
    Cieslarova, Blanka
    Oliver, Stuart
    Morris, Thomas
    CANCER RESEARCH, 2010, 70
  • [39] Phase 1, open-label, single-dose study to evaluate the effect of hepatic impairment on the pharmacokinetics and safety of futibatinib in adult subjects
    Gao, Ling
    Yamamiya, Ikuo
    Pinti, Mark
    Rondon, Juan Carlos
    Gareth, Thomas Marbury
    Tomlinson, Gareth
    Makris, Lukas
    Hangai, Nanae
    Wacheck, Volker
    CANCER RESEARCH, 2023, 83 (08)
  • [40] Pharmacokinetics, Safety, and Tolerability of Tanimilast Following Single Administrations in Subjects With Mild, Moderate, and Severe Hepatic Impairment
    Emirova, A.
    Piccino, A.
    Rizzo, E.
    Pittelli, M.
    Bellatti, P.
    Rostello, C.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
12345